Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1258- PI,    Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer
- in-vivo, CRC, NA
COX2/PTGS2↓, IL6↓, EMT↓, β-catenin/ZEB1↓, Snail↓, Symptoms∅,
1257- PI,    Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways
- ex-vivo, LiverDam, NA
*Fibronectin↓, *α-SMA↓, *COL1↓, *COL3A1↓, *TGF-β↓, *EMT↓, *MMP2↓, *α-SMA↓, *Smad7↑, *E-cadherin↑, *Vim↓, *hepatoP↑, *antiOx↑, *GSH↑, *ROS↓,
1256- PI,    Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models
- in-vitro, adrenal, PHEO - in-vivo, NA, NA
Apoptosis↑, ROS↑, TumCMig↓, TumCI↓, EMT↓, angioG↓, Necroptosis↑, MAPK↑, ERK↑,
1255- PI,  ALA,    Antileukemic effects of piperlongumine and alpha lipoic acid combination on Jurkat, MEC1 and NB4 cells in vitro
- in-vitro, CLL, NA
COX2/PTGS2↓, Casp3↑,
1254- PI,  VitC,    Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS–STAT3 pathway
- in-vivo, GC, NA
STAT3⇅, eff↑, ROS↑, Apoptosis↑,
1940- PL,    Piperlongumine Inhibits Migration of Glioblastoma Cells via Activation of ROS-Dependent p38 and JNK Signaling Pathways
- in-vitro, GBM, LN229 - in-vitro, GBM, U87MG
ROS↑, GSH↓, p38↑, JNK↑, IKKα↑, NF-kB↓, eff↓,
1946- PL,  PI,    Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling
- in-vitro, Liver, NA
eff↑, toxicity↓, TrxR↓, ROS↑, MMP↓, p38↑, Akt↓, mTOR↓,
1947- PL,    Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer
- in-vitro, GC, SGC-7901 - in-vitro, GC, NA
TrxR1↓, ROS↑, ER Stress↑, mtDam↑, selectivity↑, NO↑, TumCCA↑, mt-ROS↑, Casp9↑, Bcl-2↓, Bcl-xL↓, cl‑PARP↑, eff↓, lipid-P↑,
1948- PL,  BNL,    Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy
- in-vitro, GBM, NA
selectivity↑, ROS↑, BioAv↓, BioAv↑, Apoptosis↑, TumCCA↑, eff↑,
1949- PL,    Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
- in-vitro, CRC, HCT116 - in-vitro, Cerv, HeLa
TrxR↓, selectivity↑, ROS↑, IDO1↓,
1950- PL,    Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, Lung, A549
selectivity↑, ROS↑, SETBP1↓, cl‑Casp9↑, eff↓, FOSB↑,
1951- PL,    Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation
- in-vitro, Lung, A549
ROS↑, lipid-P↑, MMP↓, TumCCA↑, TrxR↓, eff↑,
1952- PL,  5-FU,    Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR
- in-vivo, CRC, HCT8
ROS↑, TrxR↓, eff↑, p‑Akt↓,
1953- PL,    Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation
- in-vitro, Lung, A549 - in-vitro, Nor, WI38
ROS↑, selectivity↑, TrxR↓, TumCCA↑, GSH?, H2O2↑,
1938- PL,    Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation
- Study, PSA, NA - in-vivo, NA, NA
ROS↑, Apoptosis↑, MMP↓, TumCCA↑, DNAdam↑, STAT3↓, Akt↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, Bcl-2↓, K17↓, HDAC↓, ROS↑, *IL1β↓, *IL6↓, *TNF-α↓, *IL17↓, *IL22↓,
1945- PL,  SANG,    The Synergistic Effect of Piperlongumine and Sanguinarine on the Non-Small Lung Cancer
- in-vitro, Lung, A549
toxicity∅, Apoptosis↑, TumMeta↓, ROS↑, TumCCA↑,
1944- PL,    Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
- in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
ER Stress↑, TrxR1↓, ROS↑, eff↓, Bcl-2↓, proCasp3↓, BAX↓, cl‑Casp3↑, TumCCA↑, p‑PERK↑, ATF4↑, TumCG↓, lipid-P↑, selectivity↑,
1943- PL,    Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells
- in-vitro, GBM, NA - in-vivo, NA, NA
selectivity↑, ROS↑, selectivity↑, Prx4↓, *Prx4∅, ER Stress↑, CHOP/DDIT3↑, UPR↑,
1942- PL,    Piperlongumine inhibits antioxidant enzymes, increases ROS levels, induces DNA damage and G2/M cell cycle arrest in breast cell lines
- in-vitro, BC, MCF7
ROS↑, SOD1↑, Trx1↓, Catalase↓, PrxII↓, ROS↑, GADD45A↑, P21↑, DNAdam↑, TumCCA↑,
1941- PL,    Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer
- in-vitro, HNSCC, NA
selectivity↑, eff↑, ROS↑, toxicity↑, GSH↓, GSSG↑, *GSSG∅, cl‑PARP↑, PUMA↑, GSTP1/GSTπ↓, ChemoSen↑,
1939- PL,    Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP
- in-vitro, HCC, HepG2 - in-vitro, HCC, HUH7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, ER Stress↑, selectivity↑, tumCV↓, ROS↑, GSH↓, eff↓, Ca+2↑, MAPK↑, CHOP/DDIT3↑, Dose↝,
992- PL,    Piperlongumine based nanomedicine impairs glycolytic metabolism in triple negative breast cancer stem cells through modulation of GAPDH & FBP1
- in-vivo, BC, NA
EPR↓, Glycolysis↓, GAPDH↓, GSTP1/GSTπ↝, FBPase↑,
2649- PL,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
AntiCan↑, ROS↑, GSH↓, TrxR↓, Trx↓, Apoptosis↑, TumCCA↑, ER Stress↑, DNAdam↑, ChemoSen↑, BioAv↓,
2966- PL,    A strategy to improve the solubility and bioavailability of the insoluble drug piperlongumine through albumin nanoparticles
- in-vitro, LiverDam, NA
*Half-Life↑, *BioAv↑, eff↑, ROS↑,
2971- PL,    Piperlongumine attenuates IL-1β-induced inflammatory response in chondrocytes
- NA, OS, NA
*NO↓, *PGE2↓, *iNOS↓, *COX2/PTGS2↓, *MMP3↑, *MMP13↓, *Inflam↓,
2970- PL,    Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways
- in-vitro, AML, NA
AntiAg↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↓, mTOR↓, p38↑, Casp3↑,
2969- PL,    Piperlongumine induces autophagy by targeting p38 signaling
- in-vitro, OS, U2OS - in-vitro, Cerv, HeLa
p38↑, ROS↑, GPx1∅, SOD∅, Catalase∅,
2968- PL,  Chit,    Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy
- in-vitro, GC, AGS
eff↑, Dose↝, ROS↑, BioAv↑,
2967- PL,    Piperlongumine and its derivatives against cancer: A recent update and future prospective
- Review, Var, NA
BioAv↓, BioAv↑,
2972- PL,    Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity
- in-vitro, AML, THP1
NLRP3↓, IL1β↓, LDH↓, cl‑Casp1↓, Inflam↓,
2973- PL,    The Natural Alkaloid Piperlongumine Inhibits Metastatic Activity and Epithelial-to-Mesenchymal Transition of Triple-Negative Mammary Carcinoma Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1
MMP2↓, MMP9↓, IL6↓, E-cadherin↑, ROS↑, EMT↓, Zeb1↓, Slug↓, TumMeta↓, selectivity↑, MMP2↓, GSH↓,
2995- PL,    Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover
- in-vitro, Lung, H1975 - in-vitro, Lung, PC9 - in-vivo, NA, NA
Sp1/3/4↓, cMET↓, Apoptosis↑, Cyt‑c↑, p‑ERK↓, p‑Akt↓, TumCG↓,
2996- PL,    Application of longinamide in inhibiting the activation of NLRP3 inflammasome
- NA, AD, NA - NA, Park, NA
*NLRP3↓,
2999- PL,    Piperlongumine alleviates corneal allograft rejection via suppressing angiogenesis and inflammation
- in-vivo, Nor, HUVECs
*Inflam↓, *angioG↓, *Hif1a↓, *VEGF↓, *ICAM-1↓, *VCAM-1↓, *neuroP↑,
3000- PL,    Biological and physical approaches on the role of piplartine (piperlongumine) in cancer
- in-vitro, Nor, HUVECs - in-vitro, Laryn, HEp2
Inflam↓, AntiTum↑, *α-tubulin↓, selectivity↑, HIF2a↓, MCP1/CCL2↓,
2956- PL,    Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis
- in-vitro, PC, NA
ROS↑, Ferroptosis↓, GSH↓, GPx↓, cl‑PARP∅, cl‑Casp3∅, eff↑, eff↑,
2964- PL,    Preformulation Studies on Piperlongumine
- Analysis, Nor, NA
*BioAv↓, *BioAv↑, *other↝, *eff↓,
2940- PL,    Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors
- in-vitro, PC, PANC1 - in-vitro, Lung, A549 - in-vitro, Kidney, 786-O - in-vitro, BC, SkBr3
ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1/CCND1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,
2941- PL,    Selective killing of cancer cells by a small molecule targeting the stress response to ROS
- in-vivo, BC, MDA-MB-231 - in-vitro, OS, U2OS - in-vitro, BC, MDA-MB-453
ROS↑, Apoptosis↑, selectivity↑, *ROS∅, GSH↓, GSSG↑, H2O2↑, NO↑, Half-Life?,
2942- PL,    Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems
- in-vitro, CRC, CT26 - in-vitro, CRC, DLD1 - in-vivo, CRC, CT26
ROS↑, GSH↓, TrxR↓, RadioS↑, DNAdam↑, TumCCA↑, mitResp↓, GSTs↓, OS↑,
2943- PL,    Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin
- in-vitro, CRC, HCT116 - in-vitro, Lung, A549 - in-vitro, BC, MCF7
TrxR1?, TumCD↑, ROS↑, GSH↓, eff↑,
2944- PL,    Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells
- in-vitro, Thyroid, IHH4 - in-vitro, Thyroid, 8505C - in-vivo, NA, NA
ROS↑, selectivity↑, tumCV↓, TumCCA↑, Apoptosis↑, ERK↑, Akt↓, mTOR↓, neuroP↑, Bcl-2↓, Casp3↑, PARP↑, JNK↑, *toxicity↓, eff↓, TumW↓,
2945- PL,    Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells
- in-vitro, CRC, HCT116
ROS↑, SMAD4↑, ChemoSen↑, P53↑, P21↑, BAX↑, Bcl-2↓, survivin↓, TumCMig↓,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP/DDIT3↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp/ABCB1↓, MDR1↓, MRP1/ABCC1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2/PTGS2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2947- PL,    Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer
- Review, Var, NA
TumCP↓, Apoptosis↑, TumCCA↑, ROS↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP/DDIT3↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2949- PL,    Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation
- in-vitro, GBM, LN229 - in-vitro, GBM, U87MG
selectivity↑, ROS↑, JNK↑, p38↑, GSH↓, eff↓,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
2951- PL,  AF,    Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells
- in-vitro, GBM, U87MG
GSH↓, eff↑, GSTP1/GSTπ↓,
2953- PL,    Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation
- in-vitro, Nor, NA
*ROS↑, *GSTA1↓, eff↝, *toxicity↓, ROS↑, *Hif1a↓,

Showing Research Papers: 6451 to 6500 of 8269
Prev Page 130 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   Catalase∅, 1,   Ferroptosis↓, 1,   GPx↓, 1,   GPx1∅, 1,   GSH?, 1,   GSH↓, 14,   GSSG↑, 2,   GSTP1/GSTπ↓, 2,   GSTP1/GSTπ↝, 1,   GSTs↓, 1,   H2O2↑, 2,   HO-1↑, 2,   lipid-P↑, 3,   MDA↑, 1,   NQO1↑, 1,   NRF2↑, 2,   Prx4↓, 1,   Prx4↑, 1,   PrxII↓, 1,   ROS↑, 37,   mt-ROS↑, 1,   SOD↑, 1,   SOD∅, 1,   SOD1↑, 2,   SOD2↑, 1,   Trx↓, 2,   Trx1↓, 1,   TrxR↓, 9,   TrxR1?, 1,   TrxR1↓, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mitResp↓, 1,   MMP↓, 3,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 4,   FBPase↑, 1,   GAPDH↓, 1,   Glycolysis↓, 3,   HK2↓, 2,   IDO1↓, 1,   LDH↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   p‑Akt↓, 3,   Apoptosis↑, 12,   BAX↓, 1,   BAX↑, 2,   Bcl-2↓, 7,   Bcl-xL↓, 1,   BIM↑, 1,   cl‑Casp1↓, 1,   Casp3↑, 6,   cl‑Casp3↑, 1,   cl‑Casp3∅, 1,   proCasp3↓, 1,   Casp7↑, 2,   Casp8↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 1,   Cyt‑c↑, 2,   Ferroptosis↓, 1,   JNK↑, 4,   MAPK↑, 2,   Mcl-1↓, 1,   MDM2↓, 1,   Necroptosis↑, 1,   p38↑, 6,   PUMA↑, 1,   survivin↓, 4,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 5,  

Transcription & Epigenetics(tgid=7) ⓘ

SETBP1↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 4,   p‑eIF2α↑, 1,   ER Stress↑, 6,   p‑PERK↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 6,   GADD45A↑, 1,   P53↑, 2,   PARP↑, 1,   cl‑PARP↑, 3,   cl‑PARP∅, 1,   PCNA↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   P21↑, 4,   RB1↓, 1,   p‑RB1↓, 1,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cFos↓, 1,   cMET↓, 3,   EMT↓, 4,   ERK↓, 1,   ERK↑, 2,   p‑ERK↓, 1,   FOXM1↓, 1,   p‑FOXO3↓, 1,   GSK‐3β↓, 1,   HDAC↓, 1,   mTOR↓, 5,   Nanog↓, 1,   OCT4↓, 1,   PI3K↓, 1,   PTEN↑, 1,   RAS↓, 1,   SOX2↓, 1,   STAT1↓, 1,   STAT3↓, 4,   STAT3⇅, 1,   STAT6↓, 1,   TOP2↓, 1,   TumCG↓, 4,  

Migration(tgid=13) ⓘ

AntiAg↑, 2,   AP-1↓, 1,   Ca+2↑, 1,   E-cadherin↑, 2,   FOSB↑, 1,   Ki-67↓, 2,   MMP13↓, 1,   MMP2↓, 2,   MMP3↓, 1,   MMP9↓, 3,   N-cadherin↓, 1,   Slug↓, 2,   SMAD4↑, 1,   Snail↓, 2,   SOX4↑, 1,   TumCI↓, 5,   TumCMig↓, 4,   TumCP↓, 3,   TumMeta↓, 4,   Twist↓, 2,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   ATF4↑, 2,   ATF4↝, 1,   EGFR↓, 2,   EPR↓, 1,   HIF2a↓, 1,   NO↓, 1,   NO↑, 2,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 3,   CXCR4↓, 1,   ICAM-1↓, 1,   IKKα↓, 1,   IKKα↑, 1,   IL1β↓, 1,   IL6↓, 4,   IL8↓, 1,   Inflam↓, 4,   JAK1↓, 1,   JAK2↓, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 3,   NF-kB↑, 1,   PGE2↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 4,   BioEnh↑, 1,   ChemoSen↑, 5,   Dose↝, 2,   eff↓, 8,   eff↑, 14,   eff↝, 1,   Half-Life?, 1,   Half-Life↝, 1,   MDR1↓, 1,   MRP1/ABCC1↓, 1,   RadioS↑, 3,   selectivity↑, 17,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   EGFR↓, 2,   FOXM1↓, 1,   p‑HER2/EBBR2↓, 1,   IL6↓, 4,   Ki-67↓, 2,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   K17↓, 1,   neuroP↑, 2,   OS↑, 1,   Symptoms∅, 1,   toxicity↓, 2,   toxicity↑, 1,   toxicity∅, 1,   TumW↓, 2,  
Total Targets: 201

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSH↑, 2,   GSSG∅, 1,   GSTA1↓, 1,   lipid-P↓, 1,   Prx4∅, 1,   ROS↓, 1,   ROS↑, 1,   ROS∅, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,  

Migration(tgid=13) ⓘ

COL1↓, 1,   COL3A1↓, 1,   E-cadherin↑, 1,   Fibronectin↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP3↑, 1,   Smad7↑, 1,   TGF-β↓, 1,   VCAM-1↓, 1,   Vim↓, 1,   α-SMA↓, 2,   α-tubulin↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 2,   NO↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   ICAM-1↓, 1,   IL17↓, 1,   IL1β↓, 1,   IL22↓, 1,   IL6↓, 1,   Inflam↓, 2,   PGE2↓, 1,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   eff↓, 1,   Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

hepatoP↑, 2,   neuroP↑, 1,   toxicity↓, 2,  
Total Targets: 47

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page